Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Famotidine is a widely utilized pharmacological agent belonging to the class of histamine H2-receptor antagonists. Its chemical identity is defined by the molecular formula C8H15N7O3S4 and carries the unique CAS Registry Number 76829-01-9. Structurally, it features a guanidine group linked to a thiazole ring, which facilitates its specific binding affinity for histamine receptors located on gastric parietal cells. This interaction effectively blocks the action of histamine, thereby significantly reducing both basal and stimulated gastric acid secretion without affecting pepsin or intrinsic factor production in a detrimental manner.
The primary clinical application of Famotidine involves the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and conditions characterized by pathological hypersecretion of gastric acid, such as Zollinger-Ellison syndrome. It is highly effective in promoting the healing of erosive esophagitis and preventing recurrent duodenal and gastric ulcers. Beyond these indications, it serves as a crucial prophylactic agent for stress-related mucosal damage in critically ill patients and is often employed to manage dyspepsia symptoms like heartburn and indigestion. The drug is available in various formulations, including immediate-release tablets, delayed-release tablets, oral suspensions, and injectable solutions, allowing for flexible dosing strategies tailored to individual patient needs.
Pharmacokinetically, Famotidine exhibits rapid absorption with a bioavailability of approximately 40% to 50%, reaching peak plasma concentrations within one to three hours after oral administration. It has a relatively long half-life of about 2.5 to 3.5 hours, supporting twice-daily dosing regimens for most therapeutic scenarios. The compound is primarily excreted unchanged via the kidneys, necessitating dose adjustments in patients with severe renal impairment. With a favorable safety profile compared to earlier generation H2 blockers, Famotidine remains a first-line therapy in many clinical guidelines due to its efficacy, low cost, and minimal drug-drug interactions, making it a staple in modern gastrointestinal medicine worldwide.